Product Description
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteosarcoma|Sarcoma|Bone Cancer|Soft Tissue Cancer
Phase 2: Osteosarcoma|Leiomyosarcoma|Endometrial Cancer|Sarcoma|Oncology Unspecified|Liposarcoma|Breast Cancer|Non-Small-Cell Lung Cancer|Prostate Cancer|Myelofibrosis|Lymphoma|Myeloid Leukemia|Myelodysplastic Syndrome
Phase 1: Multiple Myeloma|Lymphoma|Oncology Solid Tumor Unspecified|Gliosarcoma|Breast Cancer|Glioma|Oncology Unspecified|Glioblastoma|Heart Cancer|Sarcoma|Hepatic Insufficiency|Liver Failure|Primary Central Nervous System Lymphoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Prostate Cancer|Endometrial Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06410313 |
CHAMPIONSHIP | N/A |
Recruiting |
Peripheral Arterial Disease |
2027-01-30 |
2025-09-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06071702 |
IoNIR-002 | N/A |
Suspended |
Coronary Artery Disease|Coronary Stenosis |
2025-08-07 |
2025-09-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05364697 |
IonMAN | N/A |
Active, not recruiting |
Non-ST Elevated Myocardial Infarction|Coronary Disease|Coronary Stenosis |
2024-09-30 |
2024-11-22 |
||
NCT04761939 |
EluNIR-005 | N/A |
Completed |
Myocardial Ischemia|Coronary Stenosis |
2021-11-02 |
2022-04-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03702608 |
EluNIR-004 | N/A |
Completed |
Coronary Stenosis |
2019-03-01 |
2020-10-24 |
Primary Endpoints|Treatments |
|
NCT02828917 |
JNIR | N/A |
Completed |
Coronary Restenosis |
2018-06-01 |
2023-03-16 |
||
NCT02736344 |
BIONICS | N/A |
Completed |
Coronary Stenosis|Lyme Disease|Acute Coronary Syndrome|Angina, Stable|Coronary Artery Disease|Neuromyelitis Optica |
2017-02-01 |
11% |
2022-04-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT02834806 |
BioNIR-003 | N/A |
Completed |
Lyme Disease|Neuromyelitis Optica|Coronary Disease|Coronary Stenosis |
2017-01-16 |
2019-03-20 |
Treatments |
|
2011-000729-55 |
Oral MK8669 in Children/Adolescents with Solid Tumours(6 - <18years) | P1 |
Completed |
Primary Central Nervous System Lymphoma |
2018-05-25 |
66% |
2025-05-06 |
Treatments |
2011-003433-33 |
A Single Dose Study to Assess the Biocomparison of MK-8669 in Subjects | P1 |
Terminated |
Sarcoma |
2017-06-28 |
2025-06-28 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT01256268 |
MCC-16472 | P1 |
Completed |
Ovarian Cancer|Endometrial Cancer |
2016-02-03 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01169532 |
IND 109130 | P1 |
Completed |
Lymphoma |
2014-03-01 |
2019-03-19 |
||
NCT01295632 |
MK-8669-049 | P1 |
Completed |
Prostate Cancer|Glioblastoma|Breast Cancer|Ovarian Cancer |
2013-12-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
2011-003407-38 |
Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Therapy | P1 |
Completed |
Primary Central Nervous System Lymphoma |
2013-09-25 |
2022-03-13 |
Treatments |
|
NCT01431534 |
MK-8669-056 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2013-08-20 |
66% |
2022-05-04 |
Primary Endpoints|Treatments |
NCT01243762 |
MK-0646-027 | P1 |
Terminated |
Colorectal Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer|Sarcoma |
2012-12-04 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01220570 |
MK-8669-050 | P1 |
Completed |
Breast Cancer |
2012-12-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
NCT01212627 |
Ridaforolimus With Cetuximab | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2012-12-01 |
2021-02-17 |
Primary Endpoints |
|
2012-000335-11 |
A phase IIb study of ridaforolimus, dalotuzumab and exemestane in combination in adv breast cancer | P2 |
Completed |
Breast Cancer |
2018-03-15 |
50% |
2022-03-13 |
Treatments |
NCT00836927 |
MK-8669-038 | P2 |
Terminated |
Oncology Unspecified |
2017-04-03 |
14% |
2022-05-04 |
|
NCT01605396 |
MK-8669-064 | P2 |
Completed |
Breast Cancer |
2014-02-19 |
50% |
2022-05-04 |
Primary Endpoints|Treatments |
2010-019867-13 |
2010-019867-13 | P2 |
Completed |
Breast Cancer |
2013-10-15 |
2022-03-13 |
Treatments |
|
NCT01234857 |
MK-8669-041 AM3 | P2 |
Completed |
Breast Cancer |
2013-10-15 |
2022-05-04 |
||
2008-005942-22 |
ND | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2012-08-29 |
2022-03-12 |
Treatments |
|
2007-003462-18 |
2007-003462-18 | P3 |
Completed |
Sarcoma |
2012-12-20 |
2022-03-12 |
Treatments |